... cos unable to agree to share participation or 50/50 profit share. Negotiations with Iraq Petroleum Co (IPC) ...
1961 - Gale Group | ArchivesUnbound Iraq
Najeeb Ullah, Aftab Alam, Zainab Zainab, Ahmed A. Elhenawy, Saira Naz, Mohammad Shahidul Islam, Shujaat Ahmad, Syed Adnan Alı Shah, Manzoor Ahmad,
... glucosidase inhibitory activity. Seven derivatives 3 i (IC 50 =10.21±1.84 μM) , 3 b (IC 50 =11.14±0.99 μM) , 3 f (IC 50 =13.21±2.76 μM) , 3 h (IC 50 =14.21±0.31 μM) , 3 k (IC 50 =15.21±1.02 μM) , 3 e (IC 50 =16.21±1.32 μM), and 3 c (IC 50 =18.21±1.89 μM), in the series ... standard acarbose. However, two compounds 3 g (IC 50 =33.21±1.99 μM) and 3 d (IC 50 =42.31±2.12 μM) showed significant activity ... 3 a were found less active with IC 50 values of 82.31±0.31 and 88. ...
Tópico(s): Click Chemistry and Applications
2024 - Wiley | ChemistrySelect
Title from caption. Book.
0000 - Gale Group | Sabin 2013 02
Catherine Moermans, Chloé Brion, Grégory Bock, Sophie Graff, Sara Gerday, Haleh Nekoee, Christophe Poulet, Noémie Bricmont, Monique Henket, Virginie Paulus, Françoise Guissard, Renaud Louis, Florence Schleich,
... what it has promised?.Clin Exp Allergy. 2020; 50: 687-695Crossref PubMed Scopus (55) Google Scholar However, ... defined as a failure to decrease OCS by 50%, asthma control questionnaire (ACQ) score of ≤ 1.5, or exacerbations by 50% with persistent sputum of > 3% and blood eosinophil ... predicted, fraction of exhaled nitric oxide (Feno) of < 50 parts per billion, and control of comorbidities. The ... and observed that baseline characteristics associated with response (≥ 50% exacerbation reduction or ≥ 50% OCS dose reduction) or ...
Tópico(s): Respiratory and Cough-Related Research
2023 - Elsevier BV | CHEST Journal
3 pp. Lansdowne
0000 - Gale Group | NCCO EuropeAfrica
Mustafa Özgüroğlu, Saadettin Kılıçkap, Ahmet Sezer, Mahmut Gümüş, Igor Bondarenko, Miranda Gogishvili, Marina Nechaeva, Michael Schenker, İrfan Çiçin, Gwo Fuang Ho, Yaroslav Kulyaba, Kasimova Zyuhal, Roxana-Ioana Scheusan, Marina Chiara Garassino, Xuanyao He, M. Kaul, Emmanuel Chiebuka Okoye, Yuntong Li, Siyu Li, Jean‐François Pouliot, Frank Seebach, Israel Lowy, Giuseppe Gullo, Petra Rietschel,
... with PD-L1 tumour expression of at least 50% and no actionable biomarkers at 1-year follow- ... lung cancer with PD-L1 tumour expression of 50% or more. We randomly assigned (1:1) patients ... with a PD-L1 expression of at least 50%. We assessed adverse events in all patients who ... 105 [15%] were female). We randomly assigned 357 (50%) to cemiplimab and 355 (50%) to chemotherapy. 284 (50%) patients assigned to cemiplimab and 281 (50%) assigned to chemotherapy had verified PD-L1 expression of at least 50%. At 35 months' follow-up, among those with ...
Tópico(s): Pancreatic and Hepatic Oncology Research
2023 - Elsevier BV | The Lancet Oncology
Directory of Open Access Books (DOAB)
3 pp. Lansdowne 3 pp. Lansdowne
0000 - Gale Group | NCCO EuropeAfrica
Filip K. Knop, Vanita R. Aroda, Ruben D do Vale, Thomas Holst‐Hansen, Peter Nørkjær Laursen, Julio Rosenstock, Domenica Rubino, W. Timothy Garvey,
... the oral glucagon-like peptide-1 analogue, semaglutide 50 mg, taken once per day versus placebo for ... type 2 diabetes. The trial was done at 50 outpatient clinics in nine countries across Asia, Europe, ... web-response system to oral semaglutide escalated to 50 mg, or visually matching placebo, once per day ... least 5% at week 68 for oral semaglutide 50 mg versus placebo, assessed regardless of treatment discontinuation ... whom 667 were randomly assigned to oral semaglutide 50 mg (n=334) or placebo (n=333). The ...
Tópico(s): Metabolism, Diabetes, and Cancer
2023 - Elsevier BV | The Lancet
3 pp. Lansdowne
0000 - Gale Group | NCCO EuropeAfrica
Zejun Wang, Mahdi Ghorbani, Xi Chen, Purushottam B. Tiwari, Jeffery B. Klauda, Tinatin I. Brelidze,
... antibody.Mol. Cancer. 2011; 10: 109Crossref PubMed Scopus (50) Google Scholar, 16Weber C. de Queiroz F.M. ... IC50 of 58.1 ± 9.7 μM at +50 mV (Fig. 2, A and B, and Table ... Scholar).Table 1IC50 (μM) for imipramine inhibition at +50 mV for WT and indicated mutant EAG1 channelsChannelIC50 ( ... to compare the IC50 for imipramine inhibition at +50 mV for WT and indicated mutant channels. The ... to compare the IC50 for imipramine inhibition at +50 mV for WT and indicated mutant channels. The ... to compare the IC50 for imipramine inhibition at +50 mV for WT and indicated mutant channels. The ...
Tópico(s): Neuroscience and Neuropharmacology Research
2023 - Elsevier BV | Journal of Biological Chemistry
3 pp. Lansdowne
0000 - Gale Group | NCCO EuropeAfrica
Sandip M. Prasad, William C. Huang, Neal D. Shore, Brian Hu, Marc A. Bjurlin, Gordon A. Brown, P.P. Genov, Dimitar Shishkov, Alexandre Khuskivadze, Tosho Ganev, Dobri Marchev, И. Н. Орлов, Evgeny Kopyltsov, Vadim Zubarev, А. К. Носов, Dmitrii Komlev, Brent Burger, Sunil Raju, Andrew Meads, Mark Schoenberg,
... UGN-102 ± transurethral resection of bladder tumor and 50% for transurethral resection of bladder tumor (HR 0. ... invasive bladder cancer (NMIBC) will account for approximately 50% of the aggregate bladder cancer disease burden in ... S. Code of Federal Regulations Title 21, parts 50, 56, and 312. The study is registered with ... Two interim efficacy analyses of DFS based on 50% and 75% information fractions were planned. A stratified ... patients in the UGN-102 ± TURBT arm and 50% for patients in the TURBT monotherapy arm by ...
Tópico(s): Polyamine Metabolism and Applications
2023 - Lippincott Williams & Wilkins | The Journal of Urology
Volume 50 No 50. Memorandum by the Marquess of Landsdowne August 12, 1899. Memorandum, Government Document. From Lansdowne.
0000 - Gale Group | NCCO BritishPolitics
Brett King, Xingqi Zhang, Walter Gubelin Harcha, Jacek C. Szepietowski, Jerry Shapiro, Charles Lynde, Natasha Atanaskova Mesinkovska, Samuel H. Zwillich, Lynne Napatalung, Dalia Wajsbrot, Rana Fayyad, Amy Freyman, Debanjali Mitra, Vivek S. Purohit, Rodney Sinclair, Robert Wołk,
... and older with alopecia areata and at least 50% scalp hair loss were randomly assigned to oral ... with or without a 4-week loading dose (50 mg, 30 mg, 10 mg, 200 mg loading dose followed by 50 mg, or 200 mg loading dose followed by ... patients initially assigned to placebo switched to ritlecitinib 50 mg or 200 mg loading dose followed by 50 mg. Randomisation was done by use of an ... were randomly assigned to receive ritlecitinib 200 mg + 50 mg (n=132), 200 mg + 30 mg (n=130), 50 mg (n=130), 30 mg (n=132), 10 mg (n=63), placebo to 50 mg (n=66), or placebo to 200 mg + ...
Tópico(s): Dermatology and Skin Diseases
2023 - Elsevier BV | The Lancet
Project Gutenberg
CO/50/3, Cape of Good Hope Ordinances. 1851 - 1860
0000 - Gale Group | NCCO EuropeAfrica
Tiffany Caza, Aaron J. Storey, Samar Hassen, Christian Herzog, Rick D. Edmondson, John M. Arthur, Daniel J. Kenan, Christopher P. Larsen,
... Soc Nephrol. 2021; 32: 1666-1681Crossref PubMed Scopus (50) Google Scholar semaphorin 3B,10Sethi S. Debiec H. ... and ≥5 glomeruli by immunofluorescence microscopy, and (iii) ≤50% interstitial fibrosis and tubular atrophy. Cases where MN ... transferred to low protein binding microfuge tubes containing 50 μl of PBS-washed magnetic protein G Dynabeads ( ... automatic gain control target 100%, maximum injection time 50 milliseconds), followed by 50 × 12 m/z DIA spectra (12 m/z ... follows: PLA2R rabbit polyclonal antibody (cat #HPA012657, 1:50; Sigma-Aldrich), THSD7A rabbit polyclonal antibody (cat #AMAB91234, ...
Tópico(s): Systemic Lupus Erythematosus Research
2023 - Elsevier BV | Kidney International
National Library of Medicine (NCBI)
CO 50/6, Cape of Good Hope
0000 - Gale Group | NCCO EuropeAfrica
Christopher K. Schott, Erin Wetherbee, Rahul Khosla, Robert Nathanson, Jason P. Williams, Michael Mader, Elizabeth K. Haro, Dean L. Kellogg, Abraham Rodriguez, Kevin C. Proud, Jeremy S. Boyd, Brian Bales, Harald Sauthoff, Zahir Basrai, Dana Resop, Brian Lucas, Marcos I. Restrepo, Nilam J. Soni,
... to answer as few (1%-25%), some (26%-50%), many (51%-75%), most (76%-99%), or all ( ... 9 (19)12 (35)21 (53)Some (1%-50%)52 (43)25 (52)10 (30)17 (42)Most (> 50%)28 (23)14 (29)12 (35)2 (5) ... 6 (13)12 (35)9 (23)Some (1%-50%)63 (52)26 (54)13 (39)24 (60)Most (> 50%)32 (26)16 (33)9 (26)7 (18) ... 10 (21)8 (24)8 (20)Some (1%-50%)61 (50)25 (52)10 (30)26 (65)Most (> 50%)35 (29)13 (27)16 (47)6 (15) ... 5 (10)5 (15)11 (27)Some (1%-50%)28 (23)5 (10)8 (24)15 (38)Most (> 50%)73 (60)38 (79)21 (62)14 (35) ...
Tópico(s): Cardiac, Anesthesia and Surgical Outcomes
2023 - Elsevier BV | CHEST Critical Care
CO 50/7, Cape of Good Hope Certified Copies of Acts
0000 - Gale Group | NCCO EuropeAfrica
Twahira Begum, Roktim Gogoi, Neelav Sarma, Sudin Kumar Pandey, Mohan Lal,
... 39%. The EMCKG exhibited moderate (DPPH assay IC 50 = 15.64 ± 0.263 µg/mL; ABTS assay IC 50 = 16.93 ± 0.228 µg/mL) antioxidant activity than standard ascorbic acid (DPPH assay IC 50 = 21.24 ± 0.413 µg/mL; ABTS assay IC 50 = 21.156 ± 0.345 µg/mL). Similarly, EMCKG showed comparable activity in albumin denaturation (IC 50 = 2.93 ± 0.59 µg/mL) and protease inhibitor assay (IC 50 = 17.143 ± 0.506 µg/mL) to that of standard sodium diclofenac (IC 50 = 23.87 ± 0.729 µg/mL and IC 50 = 19.18 ± 0.271 µg/mL, respectively). The ... against Staphylococcus aureus and considerable anticholinesterase activities (IC 50 = 21.94 ± 0.109 µg/mL) compared to ...
Tópico(s): Piperaceae Chemical and Biological Studies
2023 - PeerJ, Inc. | PeerJ